Yüksel Ürün: The TALAPRO-2 trial shows a promising combo of talazoparib and enzalutamide for metastatic castration-resistant prostate cancer with HRR gene alterations

Yüksel Ürüna, Professor at Ankara University School of Medicine, shared on X/Twitter:

“The TALAPRO-2 trial shows a promising combo of talazoparib and enzalutamide for mCRPC with HRR gene alterations.

Key findings:

• Median progression-free survival not reached in talazoparib group vs. 13.8 months in control, HR 0.45
• Overall survival data remain immature, early signs are hopeful! HR 0.69
• Patients with BRCA1/BRCA2 alterations had an 80% lower risk of radiographic progression or death HR, 0.20.”

For the article click here.
Source: Yüksel Ürün/X